FDA defends generic drug labeling plan.
作者信息
Traynor Kate
出版信息
Am J Health Syst Pharm. 2014 May 15;71(10):770-3. doi: 10.2146/news140035.
PMID:24780477
Abstract
摘要
相似文献
1
FDA defends generic drug labeling plan.
Am J Health Syst Pharm. 2014 May 15;71(10):770-3. doi: 10.2146/news140035.
2
Trying times for generic medicines in the USA.美国仿制药面临艰难时期。
Lancet. 2013 Mar 30;381(9872):1072. doi: 10.1016/S0140-6736(13)60744-8.
3
Impossible? Outlawing state safety laws for generic drugs.不可能？取缔仿制药的州安全法。
N Engl J Med. 2011 Aug 25;365(8):681-3. doi: 10.1056/NEJMp1107832. Epub 2011 Aug 10.
4
New, but not improved? Incorporating comparative-effectiveness information into FDA labeling.新而未改进？将比较有效性信息纳入美国食品药品监督管理局标签中。
N Engl J Med. 2009 Sep 24;361(13):1230-3. doi: 10.1056/NEJMp0906490. Epub 2009 Aug 12.
5
A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs.关于“瘦身标签”的一项法院裁决：廉价药品面临的又一挑战。
JAMA. 2021 Oct 12;326(14):1371-1372. doi: 10.1001/jama.2021.0006.
6
Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.仿制药与品牌药制造商因产品标签不充分而承担的法律责任。
JAMA. 2018 Aug 14;320(6):547-548. doi: 10.1001/jama.2018.8408.
7
A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.一条误入歧途的公民之路——延缓仿制药竞争
N Engl J Med. 2017 Apr 20;376(16):1499-1501. doi: 10.1056/NEJMp1700202. Epub 2017 Mar 1.
8
9
Labeling may differ between generic, brand-name products.通用产品和品牌产品的标签可能有所不同。
Am J Health Syst Pharm. 2002 May 15;59(10):912, 914. doi: 10.1093/ajhp/59.10.912.
10
Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.警告标签困境。美国食品药品监督管理局允许仿制药制造商更新风险警示的规定引发强烈批评。
Mod Healthc. 2014 Jun 30;44(26):20-2.
Zotero 插件